I. POLICY/CRITERIA

VADs:

A. Use of an FDA-approved ventricular assist device (VAD) is considered medically necessary when used as labeled and for an FDA-approved indication listed below:

1. As a **bridge to transplantation** for patients who meet **all** of the following criteria:
   a. Is an approved heart transplant candidate or is a potential heart transplant candidate who has a relative contraindication(s) to heart transplantation in which there is a reasonable assurance that the contraindication can be favorably modified by the use of ventricular assist device therapy (i.e. renal dysfunction, elevated pulmonary vascular resistance, debilitation and cardiac cachexia).
   b. Has heart disease that is not amenable to another surgical procedure that would confer an equal survival advantage to heart transplantation.
   c. Has symptoms of advanced heart failure consistent with NYHA class IV limitations despite optimal medical management and requiring the initiation of inotrope therapy and / or intra-aortic balloon pump.

Requests for authorization should be submitted on the [Solid Organ Transplant](#) prior authorization form.

2. For **short-term use** (generally less than 2 weeks), as a **bridge to decision for either of the following:**
   a. patients who present with cardiogenic shock with hemodynamic instability despite optimal medical management including the use of inotrope therapy and intra-aortic balloon pump when there is a likelihood of myocardial recovery, OR
   b. post-cardiotomy surgery patients who cannot be weaned from cardiopulmonary bypass.

3. As **destination therapy** in patients meeting **all** of the following criteria:
   a. End-stage heart failure.
   b. Documented ineligibility for human heart transplantation.
c. Cardiopulmonary stress test (CPXT) with a peak oxygen consumption (i.e. peak VO₂) less than or equal to 14ml/kg or a similar validated measure (e.g. predicted VO₂, lean adjusted VO₂, VE/VCO₂ slope) demonstrating poor short and intermediate term survival AND one of the following:

- NYHA class III or IV* for at least 28 days who have received at least 14 days support with an intra-aortic balloon pump or are dependent on IV inotropic agents, with two failed weaning attempts, or
- New York Heart Association (NYHA) class IV* heart failure for at least 60 days

d. CPXT results (criteria #3c) may be waived for those patients who are inotrope dependent and were too ill to perform CPXT prior to initiation of inotropes.

*NYHA Class III = marked limitation of physical activity; less than ordinary activity leads to symptoms
*NYHA Class IV = inability to carry on any activity without symptoms; symptoms may be present at rest

4. For use to provide temporary left sided mechanical circulatory support as a bridge to cardiac transplantation for pediatric patients who meet both of the following criteria:

a. NYHA Class IV end-stage heart failure
b. Refractory to medical therapy and who are listed candidates for cardiac transplantation

5. There is growing experience that many patients experience improvements in myocardial function over time after left ventricular assist device implantation and ongoing treatment with cardiac reverse remodeling medications. This can at times be of sufficient extent to allow removal of their LVAD (long term bridge to recovery). At the present time, the likelihood of such LVAD bridge to recovery is low enough that placement of an LVAD for the expressed purpose of myocardial recovery alone is not considered standard therapy. Patients should meet criteria for LVAD implantation for one of the above indications, although there is recognition that ongoing treatment with cardiac reverse remodeling medications and periodic surveillance for myocardial recovery is advisable. At times transplantation may be delayed for a period of time to observe for myocardial recovery. Other patients who have been implanted as a destination LVAD may be able to be weaned from LVAD support.
6. VADs are often implanted emergently and without obtaining prior Plan authorization. Plan notification is required, even after implantation, since these members require case management.

7. FDA-approved percutaneous left ventricular assist devices (pVAD) (e.g., the TandemHeart and the Impella) are covered for the following indications:
   a. Providing short-term circulatory support (FDA approved for up to 6 hours) in cardiogenic shock; or
   b. As an adjunct to percutaneous coronary intervention (PCI) in the following high-risk patients:
      i. Persons undergoing unprotected left main or last-remaining-conduit PCI with ejection fraction less than 35 percent; or
      ii. Persons with three vessel disease and ejection fraction less than 30 percent.

Percutaneous VADs are considered experimental and investigational for all other indications because of insufficient evidence in the peer-reviewed literature.

B. All VADs must be implanted in a facility approved by Medicare to perform this procedure. VADs used as a bridge to transplantation, implanted at a site other than the Medicare-approved transplant center, must meet the following CMS language: The implanting site, if different than the Medicare approved transplant center, must receive written permission from the Medicare approved heart transplant center under which the patient is listed prior to implementation of the VAD.

C. Use of a non-FDA approved ventricular assist device is considered investigational.

D. A VAD is not covered if any of the following conditions are present, non-covered conditions are not limited to this list:
   1. Irreversible multiple organ dysfunction
   2. Severely restricted pulmonary function
   3. Major neurological deficit
   4. Cerebral vascular accident with significant cognitive impairment
   5. Active, systemic infection
   6. Active malignancy, except for localized basal cell cancer
   7. Long-term high-dose corticosteroid use
   8. HIV seropositivity
   9. Blood clotting disorders
   10. Age ≥80 years
Artificial Hearts:

Bridge to Transplant: An FDA-approved total artificial heart (e.g., CardioWest Total Artificial Heart), is a covered benefit when used as a bridge to transplant for transplant-eligible members who are at imminent risk of death (NYHA Class IV) due to biventricular failure who are awaiting heart transplantation. Requests for authorization should be submitted on the Solid Organ Transplant prior authorization form.

Destination Therapy: Use of a total artificial heart as a permanent treatment (i.e. as an alternative to heart transplantation) may be a covered benefit in accordance with the FDA’s Humanitarian Device Exemption if implanted in a clinical study that meets the CMS study requirements (CMS approved clinical studies are listed @ http://www.cms.hhs.gov/MedicareApprovedFacilities/06_artificialhearts.asp) Coverage in a clinical trial is defined in the Priority Health Clinical Trials medical policy.

Members receiving VADs or Artificial Hearts (pre or post-op) must have an advance care planning assessment (see Appendix A at the end of this medical policy) completed by a qualified provider. The assessment should accompany the request for a VAD or artificial heart.

II. MEDICAL NECESSITY REVIEW

Required ☒ Not Required ☐ Not Applicable ☐

III. APPLICATION TO PRODUCTS

Coverage is subject to member’s specific benefits. Group specific policy will supersede this policy when applicable.

- HMO/EPO: This policy applies to insured HMO/EPO plans.
- POS: This policy applies to insured POS plans.
- PPO: This policy applies to insured PPO plans. Consult individual plan documents as state mandated benefits may apply. If there is a conflict between this policy and a plan document, the provisions of the plan document will govern.
- ASO: For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.
- INDIVIDUAL: For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.
- MEDICARE: Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, this policy applies.
IV. DESCRIPTION

Ventricular assist devices (VADs) and total artificial hearts (TAH) may be used to sustain patients awaiting heart transplantation, to facilitate cardiac recovery in patients suffering from reversible cardiac dysfunction, and to provide permanent circulatory support in patients with end-stage heart failure (HF) who are not candidates for transplantation.

Ventricular assist devices (VADs) are used to assist the left ventricle (LVADs), the right ventricle (RVADs), or both, and removal of the native heart is not necessary; VADs do not replace the heart, but rather work with the patient’s own heart to pump sufficient blood throughout the body, and, thus, are used as auxiliary or parallel pumps. The VAD consists of a pump, a control system, and an energy supply.

There is substantial evidence that LVADs can provide effective circulatory support for patients with end-stage HF, and that the improved hemodynamics that these devices provide can help to stabilize and possibly reverse damage to myocardial tissue and secondary organs in patients waiting for transplantation, improving survival both before and after transplantation. There also is evidence to support the use of LVADs as intermediate-term support for HF patients who may subsequently recover sufficient function of the native heart to allow explantation. In addition, there is recent evidence to support the use of LVADs as permanent, or destination, therapy for end-stage HF patients who are not suitable candidates for transplantation.

A total artificial heart (TAH) is an implantable, pneumatic, biventricular support device that serves as a total replacement for both ventricles of the failing heart. Historically, the objective of implanting a TAH has been as a temporary measure to improve the likelihood of survival before and after heart transplantation in patients with end-stage heart failure (HF) who meet standard, accepted criteria for heart transplantation, who are at imminent risk of death and have no other treatment options, and for whom a compatible donor heart is unavailable. More recently, a TAH has been developed for use as destination therapy (permanent
use) in patients with severe, irreversible biventricular HF who are not candidates for other therapies, including transplantation.

V. CODING INFORMATION

**ICD-10 Codes** that may support medical necessity:

- **I11.0 – I11.9** Hypertensive heart disease
- **I13.0 – I13.2** Hypertensive heart and chronic kidney disease
- **I21.01 - I21.4** ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
- **I22.0 – I22.9** Subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
- **I42.0 – I42.9** Cardiomyopathy
- **I43** Cardiomyopathy in diseases classified elsewhere
- **I50.1 – I50.9** Heart failure
- **I51.5** Myocardial degeneration
- **I51.7** Cardiomegaly
- **I51.9** Heart disease, unspecified
- **I97.0** Postcardiotomy syndrome
- **I97.10 – I97.191** Other postprocedural cardiac functional disturbances
- **I97.710 – I97.791** Intraoperative cardiac functional disturbances
- **I97.810 – I97.89** Other intraoperative and postprocedural complications and disorders of the circulatory system, not elsewhere classified
- **R57.0** Cardiogenic shock

- **T82.221A - T82.228S** Mechanical complication of biological heart valve graft
- **T82.512A - T82.512S** Breakdown (mechanical) of artificial heart
- **T82.518A - T82.518S** Breakdown (mechanical) of other cardiac and vascular devices and implants
- **T82.519A - T82.519S** Breakdown (mechanical) of unspecified cardiac and vascular devices and implants
- **T82.522A – T82.522S** Displacement of artificial heart
- **T82.528A – T82.528S** Displacement of other cardiac and vascular devices and implants
- **T82.529A – T82.529S** Displacement of unspecified cardiac and vascular devices and implants
- **T82.532A - T82.532S** Leakage of artificial heart
- **T82.538A - T82.538A** Leakage of other cardiac and vascular devices and implants
- **T82.539A - T82.539S** Leakage of unspecified cardiac and vascular devices and implants
- **T82.592A - T82.592A** Other mechanical complication of artificial heart
- **T82.598A - T82.598S** Other mechanical complication of other cardiac and vascular devices and implants
- **T82.599A - T82.599S** Other mechanical complication of unspecified cardiac and vascular devices and implants

- **Z76.82** Awaiting organ transplant status
- **Z95.1** Presence of aortocoronary bypass graft
Z95.811 Presence of heart assist device
Z95.812 Presence of fully implantable artificial heart
Z95.9 Presence of cardiac and vascular implant and graft, unspecified

**CPT Codes:**
* No prior authorization required for removal or repositioning when performed as a separate service, or for interrogation services

- 33975 Insertion of ventricular assist device; extracorporeal, single ventricle
- 33976 Insertion of ventricular assist device; extracorporeal, biventricular
- 33977* Removal of ventricular assist device; extracorporeal, single ventricle
- 33978* Removal of ventricular assist device; extracorporeal, biventricular
- 33979 Insertion of ventricular assist device, implantable intracorporeal, single ventricle
- 33980* Removal of ventricular assist device, implantable intracorporeal, single ventricle
- 33981 Replacement of extracorporeal ventricular assist device, single or biventricular, pump(s), single or each pump
- 33982 Replacement of ventricular assist device pump(s); implantable intracorporeal, single ventricle, without cardiopulmonary bypass
- 33983 Replacement of ventricular assist device pump(s); implantable intracorporeal, single ventricle, with cardiopulmonary bypass
- 33990 Insertion of ventricular assist device, percutaneous including radiological supervision and interpretation; arterial access only
- 33991 Insertion of ventricular assist device, percutaneous including radiological supervision and interpretation; both arterial and venous access, with transseptal puncture
- 33992* Removal of percutaneous ventricular assist device at separate and distinct session from insertion
- 33993* Repositioning of percutaneous ventricular assist device with imaging guidance at separate and distinct session from insertion
- 93750* Interrogation of ventricular assist device (VAD), in person, with physician analysis of device parameters (eg, drivelines, alarms, power surges), review of device function (eg, flow and volume status, septum status, recovery), with programming, if performed, and report (no auth required)

- 0051T Implantation of a total replacement heart system (artificial heart) with recipient cardiectomy (Not covered for Priority Medicaid)
- 0052T Replacement or repair of thoracic unit of a total replacement heart system (artificial heart) (Not covered for Priority Medicaid)
- 0053T Replacement or repair of implantable component or components of total replacement heart system (artificial heart), excluding thoracic unit (Not covered for Priority Medicaid)

**HCPCS Codes** - Replacement Device, Supplies & Components
(Device and all supplies for initial unit are included in the IP stay)
| Q0478 | Power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle type |
| Q0479 | Power module for use with electric or electric/pneumatic ventricular assist device, replacement only |
| Q0480 | Driver for use with pneumatic ventricular assist device, replacement only |
| Q0481 | Microprocessor control unit for use with electric ventricular assist device, replacement only |
| Q0482 | Microprocessor control unit for use with electric/pneumatic combination ventricular assist device, replacement only |
| Q0483 | Monitor/display module for use with electric ventricular assist device, replacement only |
| Q0484 | Monitor/display module for use with electric or electric/pneumatic ventricular assist device, replacement only |
| Q0485 | Monitor control cable for use with electric ventricular assist device, replacement only |
| Q0486 | Monitor control cable for use with electric/pneumatic ventricular assist device, replacement only |
| Q0487 | Leads (pneumatic/electrical) for use with any type electric/pneumatic ventricular assist device, replacement only |
| Q0488 | Power pack base for use with electric ventricular assist device, replacement only |
| Q0489 | Power pack base for use with electric/pneumatic ventricular assist device, replacement only |
| Q0490 | Emergency power source for use with electric ventricular assist device, replacement only |
| Q0491 | Emergency power source for use with electric/pneumatic ventricular assist device, replacement only |
| Q0492 | Emergency power supply cable for use with electric ventricular assist device, replacement only |
| Q0493 | Emergency power supply cable for use with electric/pneumatic ventricular assist device, replacement only |
| Q0494 | Emergency hand pump for use with electric/pneumatic ventricular assist device, replacement only |
| Q0495 | Battery/power pack charger for use with electric or electric/pneumatic ventricular assist device replacement only |
| Q0496 | Battery for use with electric or electric/pneumatic ventricular assist device, replacement only |
| Q0497 | Battery clips for use with electric or electric/pneumatic ventricular assist device, replacement only |
| Q0498 | Holster for use with electric or electric/pneumatic ventricular assist device, replacement only |
| Q0499 | Belt/vest for use with electric or electric/pneumatic ventricular assist device, replacement only |
| Q0500 | Filters for use with electric or electric/pneumatic ventricular assist device, replacement only |
| Q0501 | Shower cover for use with electric or electric/pneumatic ventricular assist device, replacement only |
| Q0502 | Mobility cart for pneumatic ventricular assist device, replacement only |
| Q0503 | Battery for pneumatic ventricular assist device, replacement only, each |
Q0504  Power adapter for pneumatic ventricular assist device, replacement only, vehicle type
Q0506  Battery, lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0507  Miscellaneous supply or accessory for use with an external ventricular assist device
Q0508  Miscellaneous supply or accessory for use with an implanted ventricular assist device
Q0509  Miscellaneous supply or accessory for use any implanted ventricular assist device for which payment was not made under Medicare part A

Not Covered Procedures (Effective January 1, 2017)

0451T  Insertion or replacement of a permanently implantable aortic counterpulsation ventricular assist system, endovascular approach, and programming of sensing and therapeutic parameters; complete system (counterpulsation device, vascular graft, implantable vascular hemostatic seal, mechano-electrical skin interface and subcutaneous electrodes)
0452T  Insertion or replacement of a permanently implantable aortic counterpulsation ventricular assist system, endovascular approach, and programming of sensing and therapeutic parameters; aortic counterpulsation device and vascular hemostatic seal
0453T  Insertion or replacement of a permanently implantable aortic counterpulsation ventricular assist system, endovascular approach, and programming of sensing and therapeutic parameters; mechano-electrical skin interface
0454T  Insertion or replacement of a permanently implantable aortic counterpulsation ventricular assist system, endovascular approach, and programming of sensing and therapeutic parameters; subcutaneous electrode
0455T  Removal of permanently implantable aortic counterpulsation ventricular assist system; complete system (aortic counterpulsation device, vascular hemostatic seal, mechano-electrical skin interface and electrodes)
0456T  Removal of permanently implantable aortic counterpulsation ventricular assist system; aortic counterpulsation device and vascular hemostatic seal
0457T  Removal of permanently implantable aortic counterpulsation ventricular assist system; mechano-electrical skin interface
0458T  Removal of permanently implantable aortic counterpulsation ventricular assist system; subcutaneous electrode
0459T  Relocation of skin pocket with replacement of implanted aortic counterpulsation ventricular assist device, mechano-electrical skin interface and electrodes
0460T  Repositioning of previously implanted aortic counterpulsation ventricular assist device; subcutaneous electrode
0461T  Repositioning of previously implanted aortic counterpulsation ventricular assist device; aortic counterpulsation device
0462T  Programming device evaluation (in person) with iterative adjustment of the implantable mechano-electrical skin interface and/or external driver to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable aortic counterpulsation ventricular assist system, per day
0463T Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, implantable aortic counterpulsation ventricular assist system, per day

VI. REFERENCES


CMS NCD for Artificial Hearts & Related Devices @ http://www.cms.hhs.gov/MCD/viewncd.asp?ncd_id=20.9&ncd_version=4


Hayes, Inc. Total Artificial Heart, Temporary or Permanent Biventricular Support Device, July 2005 with annual updates thru June 2009.

Hayes, Inc. Left Ventricular Assist Devices (LVADs) in Adult Patients with Chronic, End-Stage Heart Failure, August 2010


Hayes, Inc. Impella Recover LP 2.5 Percutaneous Cardiac Support System (Abiomed Inc.) for Patients Undergoing High-Risk Percutaneous Coronary Intervention (PCI) March 2013 and update 2014

Hayes, Inc. Impella Recover LP 2.5 Percutaneous Cardiac Support System (Abiomed Inc.) for Emergent Hemodynamic Support in Patients with Cardiogenic Shock, April 2013 and update 2014

Ventricular Assist Devices (VADs) and Percutaneous Cardiac Support Systems, Cigna Medical Coverage Policy @ https://cignaforhcp.cigna.com/web/public/(Retrieved October 10, 2016)
APPENDIX A

ADVANCE CARE PLANNING ASSESSMENT

1. Medical history and reason for referral:

2. Patient’s understanding of current disease status and overall prognosis:

Medical care options discussed with patient:

3. Has patient completed an Advance Care Planning conversation, including designation of patient advocate as part of the advance directive, with a certified ACP facilitator*? Yes ☐ No ☐ If no, answer questions 4-9. If yes, this form is complete.

4. What are patient’s wishes/goals for remainder of life (quality of life vs. length of life; importance of physical comfort; how patient wishes to spend time, etc.)?

5. How does patient describe their current physical/mental symptoms? What is quality of life rating using QOL, HR QOL scale, SF 36 (short-form health questionnaire)?

6. Spiritual or cultural beliefs related to illness and death that would affect enrollment? Yes ☐ No ☐

7. Is advance directive complete? Yes ☐ No ☐

(i.e. Making Choices Michigan)

8. Patient has designated a durable power of attorney for healthcare? Yes ☐ No ☐

9. Does family/patient advocate support patient’s preference for medical care as outlined in advance directive? Yes ☐ No ☐

*Certified ACP facilitators are trained through the Respecting Choices® curriculum. Trained facilitators are available at health systems, Making Choices Michigan, and community organizations.